CNP and achondroplasia: Vosoritide, a synthetic CNP analog, has significantly improved long bone growth through its action on the hypertrophic chondrocytes in the cartilaginous growth plate.11, 12, 13 Studies of the use of vosoritide in infants aged 0 to 6 months with achondroplasia also suggests an improvement upon the foramen magnum surface area, as well as facial and sinus volume.13